ACHV Earnings Achieve Life Sciences, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Net income
ROE
Reported EPS history
1–28 of 28
| Q2 2026 | 2026-06-30 | -1.15 | 2026-08-11 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.19 | 2026-05-12 | 10-Q |
| FY 2025 | 2025-12-31 | -1.25 | 2026-03-24 | 10-K |
| Q3 2025 | 2025-09-30 | -0.99 | 2025-11-06 | 10-Q |
| Q2 2026 | 2025-06-30 | -0.74 | 2026-08-11 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.37 | 2026-05-12 | 10-Q |
| FY 2025 | 2024-12-31 | -1.24 | 2026-03-24 | 10-K |
| Q3 2025 | 2024-09-30 | -0.88 | 2025-11-06 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.50 | 2025-08-07 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.26 | 2025-05-13 | 10-Q |
| FY 2025 | 2023-12-31 | -1.50 | 2026-03-24 | 10-K |
| Q3 2024 | 2023-09-30 | -1.26 | 2024-11-07 | 10-Q |
| Q2 2024 | 2023-06-30 | -0.93 | 2024-08-13 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.50 | 2024-05-09 | 10-Q |
| FY 2024 | 2022-12-31 | -4.00 | 2025-03-11 | 10-K |
| Q3 2023 | 2022-09-30 | -3.24 | 2023-11-09 | 10-Q |
| Q2 2023 | 2022-06-30 | -1.89 | 2023-08-14 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.80 | 2023-05-09 | 10-Q |
| FY 2023 | 2021-12-31 | -4.08 | 2024-03-28 | 10-K |
| Q3 2022 | 2021-09-30 | -3.39 | 2022-11-14 | 10-Q |
| Q2 2022 | 2021-06-30 | -2.85 | 2022-08-11 | 10-Q |
| FY 2022 | 2020-12-31 | -5.42 | 2023-03-16 | 10-K |
| Q3 2012 | 2012-09-30 | 1.29 | 2012-11-08 | 10-Q |
| FY 2012 | 2011-12-31 | -0.98 | 2013-03-07 | 10-K |
| FY 2012 | 2011-09-30 | 0.45 | 2013-03-07 | 10-K |
| FY 2012 | 2011-06-30 | -0.67 | 2013-03-07 | 10-K |
| FY 2012 | 2011-03-31 | -0.31 | 2013-03-07 | 10-K |
| Q3 2011 | 2010-09-30 | 1.53 | 2011-11-03 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.